Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference
Feb 7, 2018
|
NEW YORK--(BUSINESS WIRE)--Feb. 7, 2018--
Rocket
Pharmaceuticals, Inc.(NASDAQ: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announced that
Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will
participate in a fireside chat at the Leerink Partners 7th
Annual Global Healthcare Conference in New York City. The fireside chat
will take place on Wednesday, February 14, 2018, at 2:00 p.m. Eastern
Time (ET).
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, undertreated
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based
gene therapy program for an undisclosed rare pediatric disease. For more
information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005145/en/
Source: Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket
Pharma, Inc.
The Alexandria Center for Life Science
430 East
29 Street, Suite 1040
New York, NY 10016
cp@rocketpharma.com
